<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137807">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819181</url>
  </required_header>
  <id_info>
    <org_study_id>WIN TAVI</org_study_id>
    <nct_id>NCT01819181</nct_id>
  </id_info>
  <brief_title>Women's INternational Transcatheter Aortic Valve Implantation Registry</brief_title>
  <acronym>WINTAVI</acronym>
  <official_title>Women's INternational Transcatheter Aortic Valve Implantation Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Society for Cardiovascular Angiography and Interventions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Society for Cardiovascular Angiography and Interventions</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate all female patients with severe aortic stenosis undergoing
      transcatheter valve implantation with commercially available valves and delivery systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WINTAVI is an international, multi-centre, prospective, observational registry. The purpose
      of this study is to collect 'real-world' data regarding the clinical utility of all
      commercially available Transcatheter Aortic Valve Implantation (TAVI) devices for
      percutaneous aortic valve implantation in female patients with severe Aortic Stenosis (AS)
      requiring treatment. Data collected in this study will provide additional information on the
      understanding of the safety and device performance in a 'real-world' setting and how to best
      treat patients with severe AS. This will include Quality of Life  questionnaires (KCCQ).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>VARC 2</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary study endpoint is the VARC 2 early safety endpoint at 30-days (all-cause mortality, all stroke [disabling and non disabling], life-threatening bleeding, stage 2 or 3 acute kidney injury [AKI], coronary artery obstruction requiring intervention, major vascular complications, repeat procedure for valve-related dysfunction).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VARC 2 and BARC</measure>
    <time_frame>30 days, 6 month, 1 year up to 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The clinical efficacy endpoint after 30-days (all-cause mortality, all stroke [disabling and non-disabling], requiring hospitalizations for valve related symptoms or worsening congestive heart failure, NYHA class III or IV, prosthetic valve dysfunction).
Additional individual safety endpoints include the following: all-cause mortality (procedural and 30-days), cardiovascular mortality, MI (peri-procedural and spontaneous), stroke (disabling and non-disabling), bleeding (life-threatening or disabling and major) and BARC type 3a-c and type 5a-b, AKI (stages 2 and 3), incidence of contrast-induced nephropathy, vascular complications (major and minor) and percutaneous closure device failure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VARC 2, NYHA, KCCQ, six-minute walk test.</measure>
    <time_frame>30 days, 6 month, 1 year up to 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Additional prosthetic valve performance endpoints include the following: prosthetic valve stenosis, prosthesis-patient mismatch, prosthetic valve regurgitation (central and paravalvular), effective orifice area and mean gradient, prosthetic valve malpositioning, TAV-in TAV deployment, prosthetic valve thrombosis, prosthetic valve endocarditis.
Additional TAVI related endpoints include the following: conduction disturbances and cardiac arrhythmias, coronary obstruction, conversion to open surgery, unplanned use of cardiopulmonary bypass, coronary obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction and cardiac tamponade.
Additional clinical benefit endpoints include the following: NYHA functional assessment, Kansas City Cardiomyopathy Questionnaire(KCCQ) and six-minute walk test.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive female patients with severe symptomatic Aortic Stenosis who are deemed
        eligible for TAVI by a multi-disciplinary team in participating sites according to local
        policy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe AS determined by echocardiogram and Doppler, defined as: mean gradient &gt;40
             mmHg or peak jet velocity &gt;4.0 m/s and an aortic valve area ≤0.8 cm2 or aortic valve
             area index ≤0.5 cm2/m2

          2. Symptomatic AS demonstrated by angina, congestive heart failure, NYHA functional
             class ≥ II, or syncope

          3. Logistic EuroSCORE  suitable for TAVI

          4. Patient must have other conditions (such as severe airways disease, porcelain aorta,
             previous thoracic radiotherapy, Childs Pugh class B and C liver disease) such that
             the multi-disciplinary team (interventional cardiologists, cardiothoracic surgeons
             and cardiac anaesthesiologists) agree that co-morbidities render SAVR of high or
             prohibitive risk.

          5. Patient has been informed of the nature of the registry and has provided full written
             informed consent according to hospital practise

        Exclusion Criteria:

          1. Patient is not an eligible candidate for TAVI

          2. Untreated clinically significant (&gt; 70% obstruction) coronary artery disease in the
             proximal segments of main branches suitable for revascularization

          3. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation

          4. Hemodynamic instability (e.g. requiring inotropic support)

          5. Active endocarditis or sepsis within  6-months prior to the study procedure

          6. Use of investigational device without CE mark
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaide Chieffo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCSSRaffaele and WINSCAI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique PASTEUR</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-pyrenees</state>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Tchetche, MD</last_name>
      <email>d.tchetche@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Didier Tchetche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jaques Cartier</name>
      <address>
        <city>Massy</city>
        <state>Paris</state>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Lefevre, MD</last_name>
      <email>t.lefevre@icps.com.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Lefevre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Parly 2</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rangueil Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>50032</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munich</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julinda Mehilli, MD</last_name>
      <phone>49891218</phone>
      <email>mehilli@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Julinda Mehilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria PO Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Tamburino, MD PhD</last_name>
      <phone>00390957436205</phone>
      <email>tambucor@unict.it</email>
    </contact>
    <investigator>
      <last_name>Corrado Tamburino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto clinico humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Presbitero, MD</last_name>
      <email>patrizia.presbitero@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Patrizia Presbitero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCSSRaffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaide Chieffo, MD</last_name>
      <phone>+390226437331</phone>
      <phone_ext>7331</phone_ext>
      <email>chieffo.alaide@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Alaide Chieffo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiac Thoracic and Vascular Sciences University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Fraccaro, MD</last_name>
      <email>chiara_fraccaro@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Chiara Fraccaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera universitaria Pisana Sezione Dipartimentale Laboratorio di Emodinamica P.O. Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sonia Petronio, MD</last_name>
      <phone>050995244</phone>
      <email>as.petronio@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna Sonia Petronio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department cardiovascular Sciences Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gennaro Sardella, MD</last_name>
      <phone>00390649979035</phone>
      <email>rino.sardella@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Gennaro Sardella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerisity of Siena, Department of Cardiovascular Diseases,Hospital Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mauriziano Hospital</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Meliga, MD</last_name>
      <email>emeliga@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Emanuele Meliga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Radboud/Nijmegen</city>
        <zip>9101</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kievit, MD</last_name>
      <email>p.kievit@cardio.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>Peter Kievit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Van Mieghem, MD</last_name>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Nicolas Van Mieghem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza.</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria-Cruz Ferrer-Gracia</last_name>
      <email>mcferrer10@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Isabel Calvo Cebollero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.scai.org/win</url>
    <description>Women in Innovations (&quot;WIN&quot;)  mission is to address sex-based disparities in cardiovascular diagnosis, treatment and outcomes through innovative educational and research activities.</description>
  </link>
  <reference>
    <citation>Buchanan GL, Chieffo A, Montorfano M, Maisano F, Latib A, Godino C, Cioni M, Gullace MA, Franco A, Gerli C, Alfieri O, Colombo A. The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN™ and Medtronic CoreValve ReValving System® devices: the Milan registry. EuroIntervention. 2011 Sep;7(5):556-63. doi: 10.4244/EIJV7I5A91.</citation>
    <PMID>21930459</PMID>
  </reference>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23. doi: 10.1016/j.jtcvs.2012.09.002. Epub 2012 Oct 16. Review.</citation>
    <PMID>23084102</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <reference>
    <citation>Hayashida K, Morice MC, Chevalier B, Hovasse T, Romano M, Garot P, Farge A, Donzeau-Gouge P, Bouvier E, Cormier B, Lefèvre T. Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis. J Am Coll Cardiol. 2012 Feb 7;59(6):566-71. doi: 10.1016/j.jacc.2011.10.877.</citation>
    <PMID>22300690</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>women</keyword>
  <keyword>aortic stenosis</keyword>
  <keyword>VARC2</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
